NIHS 医薬品安全性情報 Vol.16 No.012018/0111/

Carafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ

  Carafate

Guideline for the Development of Liposome Drug …

4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a

  Molecular, Weight

Guideline for Bioequivalence Studies of Generic …

1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン

Since 1874 遺伝子治療用製品の開発における 国内 …

遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正

Guideline for Bioequivalence Studies for Different ...

2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an

  Guidelines, Studies, Solid, Dosage, Guideline for bioequivalence studies for, Bioequivalence, Solid dosage

Clinical Pharmacokinetic Studies of Pharmaceuticals

- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on

  Pharmaceutical, Clinical, Studies, Clinical pharmacokinetic studies of pharmaceuticals, Pharmacokinetic

平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp

平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-

毒物及び劇物取締法Q＆A - nihs.go.jp

1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4

European Medicines Agency - NIHS

What is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment

  Management, European, Quality, Risks, Agency, Quality risk management, Medicine, European medicines agency, Nihs, Ich q9

ICH Q9 ‘Quality Risk Management’ - NIHS

ICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company

  Management, Quality, Risks, Nihs, Ich q9 quality risk management nihs, Ich q9 quality risk management

All NDA, ANDA, and AADA Holders - ECA Academy

manufacture of the IR dosage form. These data may include parameters such as mixing time, mixing speed, and blend assays. Thus, for future level 1 SUPAC-IR changes,

  Nada, Supac, Holder, And aada holders, Aada

fDA Guidance for Industry Dissolution Testing of Immediate ...

biopharmaceutics and CMC review sraff in the Office of Phannaceutical Science (OPS). For l\'DAs, the specifications should be based on the dissolution characteristics of batches used in pivotal

  Testing, Guidance, Industry, Dissolution, Fda guidance for industry dissolution testing

Dissolution Testing for Poorly Soluble Drugs: A Continuing ...

Dissolution Technologies | AUGUST 2010 25 Sink is sink condition calculated as C S /CD (where C D is the concentration of compound in the bulk medium) and should be greater than or equal to 3.

  Testing, Soluble, Dissolution, Poorly, Dissolution testing for poorly soluble

Scale-up of Tablet Manufacturing

Scale-up of Tablet Manufacturing Jari Pajander, PhD Senior Research Scientist Mobile Course on QbD and PAT February 3rd 2015 University of Eastern Finland, Kuopio, Finland

  Scale, Manufacturing, Tablets, Scale up of tablet manufacturing

Topical Drug Products Regulatory Requirements (USA)

Topical Drug Products Regulatory Requirements (USA) Vinod P. Shah, Ph. D., FIP Scientific Secretary

  Product, Optical, Drug, Requirements, Regulatory, Topical drug products regulatory requirements

PROPOSAL TO WAIVE IN VIVO BIOEQUIVALENCE …

working document qas/04.109/rev.1 page 1 world health organization organisation mondiale de la sante proposal to waive in vivo bioequivalence requirements for the …

  Health, Requirements, World health organization, World, Organization, Vivo, Bioequivalence, Waive, Waive in vivo bioequivalence, Waive in vivo bioequivalence requirements for the